Research programme: phosphodiesterase III inhibitors - VIVUS
Latest Information Update: 18 Sep 2006
At a glance
- Originator VIVUS
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Erectile dysfunction in USA (unspecified route)
- 12 Jan 2001 New profile
- 12 Jan 2001 Preclinical development for Erectile dysfunction in USA (Unknown route)